Biologics for psoriasis in <scp>COVID</scp> ‐19 era: What do we know?
Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Gabriella Fabbrocini
Abstract
stressed the importance of a therapeutic reassessment of all psoriatic patients, chronically treated with immunosuppressive drugs in the pandemic coronavirus disease (COVID)-19 era. The literature, mass media, and information campaigns are daily focusing on preventive measures, risk factors, and class of subjects which are at increased risk, in order to sensitize the general population and limit behaviors which could facilitate virus diffusion. We agree that whether stopping or not these
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPsoriasisPandemicMEDLINEComputational biologyVirologyDermatologyInternal medicineInfectious disease (medical specialty)BiologyDiseaseOutbreakBiochemistryPsoriasis: Treatment and PathogenesisCOVID-19 Clinical Research StudiesSarcoidosis and Beryllium Toxicity Research